US EditionAstrazeneca in ASCO 2025: More than 80 Abstracts, 20 Drugs and 2 Plenary
Summary by redaccionmedica.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
AstraZeneca continues to advance in its ambition to eliminate cancer as a cause of death, and demonstrates this with the presentation of new data from its diverse and consolidated portfolio of products during the annual congress of the American Society of Clinical Oncology (ASCO), to be held from 30 May to 3 June 2025. In this event, the company will show more than 80 abstracts that gather results from 20 drugs, both approved and developing. Amo…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
